A.V. Zaborovskiy (1), N.A. Pyataev (2), L.A. Tararina (1), K.G. Gurevich (1), I.V. Maev (1), I.S. Кrysanov (3), D.V. Yunina (1)
1-A.I. EvdokimovMoscow State University of Medicine and Dentistry, Moscow, Russian Federation, 127473;
2-N.P. Ogarev Mordovia State University, Saransk, Russian Federation, 430005;
3-Moscow State University of Food Production, Medical and Social Technologies Institute, Moscow, Russian Federation, 125080

At present, various antineoplastic agents are widely used to treat cancer. There are certain problems associated with their use, such as the inhibition of the pool of dividing cells, poor tolerance and efficiency. Targeted therapy also has several disadvantages. At first it can be used only for a small number of tumors. In addition, its use is commonly limited by the high cost.Therefore, new anticancer drugs are currently under development, but with taking into account this as a lengthy and expensive process, we should pay attention to the possibility of more efficient use of existing drugs. The possibility of targeted drug delivery with the use of various kinds of carriers is widely discussed. Currently, there is a number of drugs used for the targeted transport. Most of them are prepared at the preclinical stage of development. Nano surfaces drugs are of particular interest in view of all mentioned above. In this review the latest data on the different types of carriers for targeted delivery of the currently available chemotherapeutic drugs, as well as features of pharmacokinetics of these drugs are presented.
chemotherapy, nanocarriers, directed transport